Primary outcomes by 1q21+ status for isatuximab-treated patients with relapsed/refractory multiple myeloma: subgroup analyses from ICARIA-MM and IKEMA

por Martin, Tom, Richardson, Paul G., Facon, Thierry, Moreau, Philippe, Perrot, Aurore, Spicka, Ivan, Bisht, Kamlesh, Inchauspé, Marlene, Casca, France, Macé, Sandrine, van de Velde, Helgi, Suzuki, Kenshi
Publicado 2022

Subgroup analysis of ICARIA‐MM study in relapsed/refractory multiple myeloma patients with high‐risk cytogenetics

por Harrison, Simon J., Perrot, Aurore, Alegre, Adrian, Simpson, David, Wang, Ming Chung, Spencer, Andrew, Delimpasi, Sosana, Hulin, Cyrille, Sunami, Kazutaka, Facon, Thierry, Vlummens, Philip, Yong, Kwee, Campana, Frank, Inchauspé, Marlène, Macé, Sandrine, Risse, Marie‐Laure, van de Velde, Helgi, Richardson, Paul
Publicado 2021